About Zydus Lifesciences Limited

Zydus Lifesciences Limited is an India-headquartered lifesciences company with two integrated businesses: pharmaceuticals and consumer health and wellness . The company operates a network of 39 manufacturing facilities globally, 16 of which are USFDA inspected, underscoring its scale and quality focus; capabilities span oral solids, injectables, nasals, topicals, transdermal patches, and biologics including monoclonal antibodies and antibody–drug conjugates . Its global footprint is reflected in FY25 revenue from operations of Rs 232,415 million, with contributions from India (Rs 92,530 million), the US (Rs 111,411 million), and other markets (Rs 28,474 million). 

A brief capital history dates back to May 15, 1995 (first equity allotment), with an Initial Public Offer (IPO) in February–March 2000, marking key milestones in its evolution . The company positions manufacturing as a strategic capability to deliver safe, effective and affordable medicines worldwide.

Zydus Lifesciences Limited’s Business Segments

• Pharmaceuticals: An integrated operation spanning research, development, production, marketing and distribution of pharmaceutical products. The portfolio includes Active Pharmaceutical Ingredients (API), human formulations, and animal health and veterinary products. FY25 segment revenue: Rs 205,439 million.
• Consumer Products: Development, production, marketing and distribution of differentiated health and wellness products. FY25 segment revenue: Rs 26,976 million.

Zydus Lifesciences Limited Key Management

• Pankaj R. Patel, Chairman
• Dr. Sharvil P. Patel, Managing Director
• Nitin D. Parekh, Chief Financial Officer

Latest Updates on Zydus Lifesciences Limited

• Strategic acquisition: The company announced plans to acquire 100% of Amplitude for a total consideration of Euro 300 million, subject to regulatory approvals; the simplified cash tender offer filing with the French AMF is expected after approvals, with completion of the block acquisition and filing targeted by end-December 2025.
• R&D and technology: Zydus invested Rs 11,838.00 million in R&D in FY25 and imported/absorbed multiple manufacturing technologies; capital investment during the year was Rs 267.87 million.
• Sustainability and energy: The company advanced renewable energy use, including >1,000 MWh in-house solar generation, >80,000 MWh hybrid renewable power purchases, and >40,000 MT biomass fuel usage, to reduce environmental impact.
• CSR impact: Total CSR spend in FY25 was Rs 640.01 million. Initiatives included “Green Gujarat 2.0,” engaging over 15,000 employees and 12,000 students to create 1.34 lakh native seed balls dispersed by drone in Gandhinagar.
• Recognitions: Honors included Responsible Business of the Year 2024 (SABERA), “Most Innovative and Inventive Lifesciences Company of the Year 2024,” multiple communications awards for the “Easiest Exam” breast cancer awareness campaign, and Fortune India’s “India’s Best CEOs of 2024” (health and lifesciences) for the Managing Director.